On-Demand CE for Nurse Practitioners

Earn CME on your time and at your own pace with these on-demand activities

Clinical Treatment Scenarios: Vitiligo Pathogenesis and the Role of JAK Inhibition – An In the Clinic Activity

CE Information
0.75 CME credits
Completion Time
45 minutes
Available Until
October 23, 2024
Ready to start this activity?
Already registered? Please log in to see your registration information.
You will be redirected to the association site for Integrity Continuing Education to complete your registration.


Clinical Topics
Dermatologic Disease

“If you’ve seen one patient with vitiligo…you’ve seen one patient with vitiligo,” vitiligo expert Dr. David Rosmarin is fond of saying. This relatively common dermatologic disorder can present in a wide variety of ways and its impact on patients’ quality of life can be profound yet highly individual. As the pathogenesis of vitiligo began to reveal itself, it became clear that this autoimmune inflammatory disease is medical, not cosmetic, and can be managed by blocking aberrant signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. However, until July 2022, there was no FDA-approved treatment that could accomplish this and restore the pigment lost to the destruction of melanocytes on the face, hands, or anywhere on the body. There is now a new treatment, ruxolitinib cream 1.5%, approved for use by adolescents and adults with nonsegmental vitiligo of any severity and in all parts of the body.

Join Dr. Rosmarin as he presents information about this and other emerging JAK inhibitors and offers ideas and treatment recommendations for case study patients that are likely to resemble, but not replicate, your highly individual vitiligo patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Improve clinicians’ knowledge of the pathogenesis of vitiligo
  • Describe the role of the JAK/STAT pathway in vitiligo
  • Recall clinical trial data for new and emerging therapies for vitiligo


David Rosmarin
David Rosmarin MD

Chair of Dermatology
Kampen-Norins Scholar
Indiana University School of Medicine
Indianapolis, Indiana

Dr Rosmarin is a clinical scientist and vice chair for research and education at Tufts Medical Center in Boston, MA, focusing on clinical trials for inflammatory skin disorders. He earned his medical degree at New York University, completing dermatology residency training in the Boston University-Tufts combined training program and a fellowship at Brigham and Women’s Hospital. Dr Rosmarin joined Tufts Medical Center in 2013 as a clinical trial investigator and became the director of the residency program and the clinical trials unit in 2016. Dr Rosmarin is leading the development of a topical Janus kinase (JAK) inhibitor to repigment the skin in patients with vitiligo. He was the first to use dupilumab as a treatment for bullous pemphigoid. For hidradenitis suppurativa, Dr Rosmarin is pioneering the use of anti- IL-17A and anti-IL-23 antibodies as novel treatments. He has led research on the use of oral JAK inhibitors to treat connective tissue diseases, such as systemic lupus erythematosus and scleroderma. He also focuses on other inflammatory skin disorders, such as psoriasis, atopic dermatitis, and alopecia areata.

CE Information

This activity offers 0.75 CME credits to attendees.

Accredited by Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians..

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.



Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

David Rosmarin, MD
Consultant: AbbVie, Abcuro, AltruBio, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Recludix, Regeneron, Revolo Biotherapeutics, Sanofi, Sun Pharma, UCB, Viela Bio
Research: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron
Speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermavant, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Activity Content

0% Complete
8 questions
Duration: 42 minutes | Quality: HD
Course Evaluation
18 questions
7 questions
Access your certificate

Register For This Activity

This activity was posted by Integrity Continuing Education. You will be redirected to their site to complete your registration.

On Demand Access